The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer

Journal of Thoracic and Cardiovascular Surgery

Volumn 139, Issue 4, 2010, Pages

  Evans III, Nathaniel R ^a   Li, Shuang ^b   Wright, Cameron D ^a   Allen, Mark S ^c   Gaissert, Henning A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOMA; COMORBIDITY; FEMALE; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; LOBECTOMY; LUNG CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; REOPERATION; SURGICAL MORTALITY; SURGICAL RISK;

EID: 77949475194     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.11.070     Document Type: Article

References (15)

1. Martin J., Ginsberg R.J., Abolhoda A., Bains M.S., Downey R.J., Korst R.J., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 72 (2001) 1149-1154
2. Roberts J.R., Eustis C., Devore R., Carbone D., Choy H., and Johnson D. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg 72 (2001) 885-888
3. Venuta F., Anile M., Diso D., Ibrahim M., De Giacomo T., Rolla M., et al. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg 31 (2007) 714-717
4. Wright C.D., Gaissert H.A., Grab J.D., O'Brien S.M., Peterson E.D., and Allen M.S. Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model. Ann Thorac Surg 85 (2008) 1857-1865
5. Ferguson M.K., Gaissert H.A., Grab J.D., and Sheng S. Pulmonary complications after lung resection in the absence of chronic obstructive pulmonary disease-the predictive role of diffusing capacity. J Thorac Cardiovasc Surg 138 (2009) 1297-1302 Epub 2009 Sep 26
6. Boffa D.J., Allen M.S., Grab J.D., Gaissert H.A., Harpole D.H., and Wright C.D. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg 135 (2008) 247-254
7. Rosell R., Gomez-Codina J., Camps C., Javier Sanchez J., Maestre J., Padilla J., et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26 (1999) 7-14
8. Roth J.A., Atkinson E.N., Fossella F., Komaki R., Bernadette Ryan M., Putnam Jr. J.B., et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21 (1998) 1-6
9. Berghmans T., Paesmans M., Meert A.P., Mascaux C., Lothaire P., Lafitte J.J., et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49 (2005) 13-23
10. Depierre A., Milleron B., Moro-Sibilot D., Chevret S., Quoix E., Lebeau B., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20 (2002) 247-253
11. Mattson K.V., Abratt R.P., ten Velde G., and Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol 14 (2003) 116-122
12. Doddoli C., Barlesi F., Trousse D., Robitail S., Yena S., Astoul P., et al. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 130 (2005) 416-425
13. Albain K.S., Rusch V.W., Crowley J.J., Rice T.W., Turrisi III A.T., Weick J.K., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13 (1995) 1880-1892
14. Albain K.S., Scott C.B., and Rusch V.R. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 22 (2003) 621
15. Robinson L.A., Wagner Jr. H., and Ruckdeschel J.C. Treatment of stage IIIA non-small cell lung cancer. Chest 123 (2003) 202S-220S